UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 41

Sortiert nach

Clinical Trial of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Older Adults With Type 2 Diabetes

Diabetes care, 2005-07, Vol.28 (7), p.1568-1573

2005

Volltextzugriff (PDF)

Prandial Premixed Insulin Analogue Regimens Versus Basal Insulin Analogue Regimens in the Management of Type 2 Diabetes: An Evidence-Based Comparison

Clinical therapeutics, 2007-01, Vol.29 (6), p.1254-1270

2007

Volltextzugriff (PDF)

Human regular U‐500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study

Diabetes, obesity & metabolism, 2020-03, Vol.22 (3), p.434-441

2020

Volltextzugriff (PDF)

Does Microalbuminuria Predict Diabetic Nephropathy?

Diabetes care, 2001-09, Vol.24 (9), p.1560-1566

2001

Volltextzugriff (PDF)

Simulation-Based Evaluation of Dose Titration Algorithms for U-500R Insulin by Pump in Subjects with Type 2 Diabetes

Journal of diabetes science and technology, 2021-09, Vol.15 (5), p.1195-1197

2021

Volltextzugriff (PDF)

Efficacité et tolérance similaires de l’insuline glargine LY2963016 et de l’insuline glargine (Lantus ® ) chez les patients diabétiques de type 2 dans les groupes d’âge (< 65 ans, ≥ 65 ans)

Diabetes & metabolism, 2017-03, Vol.43 (2), p.A83

2017

Volltextzugriff (PDF)

CA-095 - Efficacité et tolérance similaires de l’insuline glargine LY2963016 et de l’insuline glargine (Lantus®) chez les patients diabétiques de type 2 dans les groupes d’âge (< 65 ans, ≥ 65 ans)

Diabetes & metabolism, 2017-03, Vol.43 (2), p.A83-A83

2017

Volltextzugriff (PDF)

Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus® Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation

Diabetes therapy, 2018-08, Vol.9 (4), p.1469-1476

2018

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin Requirements

Journal of diabetes science and technology, 2022-03, Vol.16 (2), p.401-407

2022

Volltextzugriff (PDF)

CA-086 - Caractéristiques des patients diabétiques de type 2 (DT2) traités par insuline glargine U-100 et ayant atteint un taux d’HbA1c < 53 mmol/mol (< 7 %) ou une réduction du taux d’HbA1c ≥ 11 mmol/mol (≥ 1 %)

Diabetes & metabolism, 2017-03, Vol.43 (2), p.A79-A80

2017

Volltextzugriff (PDF)

Caractéristiques des patients diabétiques de type 2 (DT2) traités par insuline glargine U-100 et ayant atteint un taux d’HbA 1c < 53 mmol/mol (< 7 %) ou une réduction du taux d’HbA 1c ≥ 11 mmol/mol (≥ 1 %)

Diabetes & metabolism, 2017-03, Vol.43 (2), p.A79-A80

2017

Volltextzugriff (PDF)

Improving Diabetes Processes of Care in Managed Care

Diabetes care, 2003-10, Vol.26 (10), p.2722-2727

2003

Volltextzugriff (PDF)

Lilly Insulin Glargine Versus Lantus® in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5)

Diabetes therapy, 2019-02, Vol.10 (1), p.189-203

2019

Volltextzugriff (PDF)

Similar Efficacy and Safety of Basaglar® and Lantus® in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study

Diabetes therapy, 2018-04, Vol.9 (2), p.827-837

2018

Volltextzugriff (PDF)

Similar Efficacy and Safety of LY2963016 Insulin Glargine and Insulin Glargine (Lantus®) in Patients with T2D in Age Groups (<65, ≥65 Years)

Canadian journal of diabetes, 2016-10, Vol.40 (5), p.S40-S40

2016

Volltextzugriff (PDF)

Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2

GaBI Journal, 2018-06, Vol.7 (2), p.56-62

2018

Volltextzugriff (PDF)

Effects of Blood Glucose Rate of Changes on Perceived Mood and Cognitive Symptoms in Insulin-Treated Type 2 Diabetes

Diabetes care, 2007-08, Vol.30 (8), p.2001-2002

2007

Volltextzugriff (PDF)

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine

Diabetes therapy, 2017-06, Vol.8 (3), p.545-554

2017

Volltextzugriff (PDF)

Addition of insulin to oral therapy in type 2 diabetes

The New England journal of medicine, 2008-03, Vol.358 (11), p.1197

2008

Volltextzugriff (PDF)

Addition of Insulin to Oral Therapy in Type 2 Diabetes

The New England journal of medicine, 2008-03, Vol.358 (11), p.1197-1198

2008

Volltextzugriff (PDF)

Impact of a critical pathway on inpatient management of diabetic ketoacidosis

Diabetes research and clinical practice, 2003-10, Vol.62 (1), p.23-32

2003

Volltextzugriff (PDF)

Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus.sup.[R] Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation.(Original Research)

Diabetes therapy, 2018-08, Vol.9 (4), p.1469

2018

Volltextzugriff (PDF)

How Various Plasma Glucose (PG) Measures Correlate with A1C in Insulin-treated Type 2 Diabetes (T2D)

Canadian journal of diabetes, 2008, Vol.32 (4), p.325-325

2008

Volltextzugriff (PDF)

Case Study: Hypertriglyceridemia in a Woman With Insulin Resistance

Clinical diabetes, 2001-09, Vol.19 (4), p.183-184

Ilag, Liza L

2001

Volltextzugriff (PDF)

Similar Efficacy and Safety of Basaglar.sup.[R] and Lantus.sup.[R] in Patients with Type 2 Diabetes in Age Groups ( 65 Years, [greater than or equal to] 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study

Diabetes therapy, 2018-04, Vol.9 (2), p.827

2018

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(41)

Sprache

Englisch
(41)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(18)
Science & Technology
(18)
Endocrinology & Metabolism
(15)
Diabetes
(13)
Humans
(12)
Insulin
(11)
Type 2 Diabetes
(11)
Insulin Glargine
(10)
Diabetes Mellitus, Type 2 - Drug Therapy
(9)
Biological And Medical Sciences
(7)
Diabetes. Impaired Glucose Tolerance
(6)
Endocrine Pancreas. Apud Cells
(6)
Endocrinopathies
(6)
Medical Sciences
(6)
Clinical Trials
(5)
Drug Therapy
(5)
Hypoglycemia
(5)
Insulin - Analogs & Derivatives
(5)
Insulin - Therapeutic Use
(5)
Insulin, Long-Acting
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical Trial of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Older Adults With Type 2 Diabetes

Prandial Premixed Insulin Analogue Regimens Versus Basal Insulin Analogue Regimens in the Management of Type 2 Diabetes: An Evidence-Based Comparison

Human regular U‐500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study

Does Microalbuminuria Predict Diabetic Nephropathy?

Simulation-Based Evaluation of Dose Titration Algorithms for U-500R Insulin by Pump in Subjects with Type 2 Diabetes

Efficacité et tolérance similaires de l’insuline glargine LY2963016 et de l’insuline glargine (Lantus ® ) chez les patients diabétiques de type 2 dans les groupes d’âge (< 65 ans, ≥ 65 ans)

CA-095 - Efficacité et tolérance similaires de l’insuline glargine LY2963016 et de l’insuline glargine (Lantus®) chez les patients diabétiques de type 2 dans les groupes d’âge (< 65 ans, ≥ 65 ans)

Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus® Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation

Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin Requirements

CA-086 - Caractéristiques des patients diabétiques de type 2 (DT2) traités par insuline glargine U-100 et ayant atteint un taux d’HbA1c < 53 mmol/mol (< 7 %) ou une réduction du taux d’HbA1c ≥ 11 mmol/mol (≥ 1 %)

Caractéristiques des patients diabétiques de type 2 (DT2) traités par insuline glargine U-100 et ayant atteint un taux d’HbA 1c < 53 mmol/mol (< 7 %) ou une réduction du taux d’HbA 1c ≥ 11 mmol/mol (≥ 1 %)

Improving Diabetes Processes of Care in Managed Care

Lilly Insulin Glargine Versus Lantus® in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5)

Similar Efficacy and Safety of Basaglar® and Lantus® in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study

Similar Efficacy and Safety of LY2963016 Insulin Glargine and Insulin Glargine (Lantus®) in Patients with T2D in Age Groups (<65, ≥65 Years)

Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2

Effects of Blood Glucose Rate of Changes on Perceived Mood and Cognitive Symptoms in Insulin-Treated Type 2 Diabetes

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine

Addition of insulin to oral therapy in type 2 diabetes

Addition of Insulin to Oral Therapy in Type 2 Diabetes

Impact of a critical pathway on inpatient management of diabetic ketoacidosis

Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus.sup.[R] Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation.(Original Research)

How Various Plasma Glucose (PG) Measures Correlate with A1C in Insulin-treated Type 2 Diabetes (T2D)

Case Study: Hypertriglyceridemia in a Woman With Insulin Resistance

Similar Efficacy and Safety of Basaglar.sup.[R] and Lantus.sup.[R] in Patients with Type 2 Diabetes in Age Groups ( 65 Years, [greater than or equal to] 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study

Suchergebnisse filtern